Morningstar - Lithia Motors Inc. Class A (LAD) Lithia Makes Another Big Acquisition With DTLA

Report

Morningstar

David Whiston, CFA, CPA, CFE

EUR 101.80 For Business Accounts Only

Lithia Makes Another Big Acquisition With DTLA

Lithia Motorsâ€™ management said during its July 28 earnings call that the acquisition pipeline was full and would get even more full this year. Support for this statement came Aug. 8 when the company announced its second large acquisition of the year, Downtown Los Angeles Auto Group. Management expects DTLA to add $1 billion in annualized revenue and $0.55 in annualized earnings per share, so it increased its 2017 EPS guidance to $8.55-$8.70 from $8.35-$8.50. We are taking our 2017 EPS forecast u...

09/08/2017 14 EN

Underlying

Lithia Motors Inc. Class A

Lithia Motors is a providers of personal transportation solutions. The company's segments are Domestic, Import and Luxury. The company's Domestic segment is comprised of retail automotive franchises that sell new vehicles manufactured by Chrysler, General Motors and Ford. The company's Import segment is comprised of retail automotive franchises that sell new vehicles manufactured primarily by Honda, Toyota, Subaru, Nissan and Volkswagen. The company's Luxury segment is comprised of retail automotive franchises that sell new vehicles manufactured primarily by BMW, Mercedes-Benz and Lexus. The franchises in each segment also sell used vehicles, parts and automotive services, and automotive finance and insurance products.

See profile

US5367971034 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

David Whiston, CFA, CPA, CFE

Other Reports on these Companies

Moody's Investors Service

Moody's Ratings announces completion of a periodic review of ratings of Lithia Motors, Inc.

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Lithia Motors, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 30 April 2025 in which we reassessed the appropriateness of the ratings in the context ...

May 5, 2025 May 5, 2025 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommendations to "buy the pullbacks" since the day before the election, and also throughout the second hal...

EUR 42.71

February 19, 2025 February 19, 2025 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Local Tops for 10-Year Yield, DXY, and WTI Crude Oil Our outlook remains bullish, and since late-December we have been suggesting to use the pullback as a buying opportunity. Our most recent and highest conviction "buy the dip" call came last week (1/14/25 Compass) amid all the major indexes testing key supports (S&P 500, Nasdaq 100, DJI, S&P Mid Caps, VXF, Russell 2000, ARKK, and SMH), bullish breadth divergences, and other ongoing risk-on signals. Those dip buys are finally paying off, with all of the aforementioned indexes breaking out from their 1+ month consolidations, and small- and mid...

EUR 42.71

January 23, 2025 January 23, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Lithia Makes Another Big Acquisition With DTLA

Moody's Ratings announces completion of a periodic review of ratings of Lithia Motors, Inc.

Vermilion Compass: Weekly Equity Strategy

Vermilion Compass: Weekly Equity Strategy

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe